ZAP Surgical Systems has attracted $36 million in new funding to accelerate its global expansion. The medical technology company, based in California, announced the receipt of funds on October 19, 2026. The financing was led by Catalio Capital Management with support from Baheal, ZAP's strategic partner in China.
The investment reflects confidence in the company's robotic radiosurgery technology and its commercial potential. With the received capital, ZAP plans to deploy its ZAP-X Gyroscopic Radiosurgery platform in academic medical centers, community hospitals, and private physician practices. Furthermore, the company is increasing production to meet growing global demand. To date, ZAP has delivered its fiftieth unit to a client, and approximately 10,000 patients have been treated.
ZAPX is the sixth system developed by ZAP, which was founded in 2014 by the late neurosurgeon John R. Adler. The ZAP-X platform allows radiation delivery from over 1000 beam angles. The system is equipped with integrated shielding, eliminating the need for a radiation bunker in a standard facility, and utilizes a modern linear accelerator instead of radioactive cobalt. These design choices aim to reduce installation costs and simplify procedures, potentially making treatment accessible to hospitals and outpatient providers with limited infrastructure. The company works with both traditional healthcare providers and underserved markets.
Regarding its growth model, the company intends to strengthen its position in the United States and deepen cooperation with Baheal in China. Nicolas von Gionno, a physician and investor at Catalio, noted that this funding demonstrates belief in ZAP's global potential. He will also join the company's board of directors as an observer, adding that intelligent robotics can help reduce healthcare costs while simultaneously improving treatment standards. Catalio specializes in investments in healthcare and artificial intelligence across private, public, and credit markets.
In addition to treating brain tumors, ZAP is exploring neuromodulation—a novel approach involving precisely targeted low-dose ionizing radiation. The company and its partners have investigated the neuromodulatory effects of this approach on various mammalian brain models. ZAP also reported preliminary results from a pilot human study conducted with patients suffering from treatment-resistant depression. This early data has spurred plans for broader multi-center clinical trials, initially focusing on treatment-resistant depression and addiction.
Founder and CEO of ZAP, John R. Adler, stated that neuroscience could undergo significant therapeutic advancements in the next decade. He believes that mission-aligned investment partners will be crucial for expanding access to non-invasive treatment methods. This new funding follows ZAP's $78 million Series E round in November 2024, led by Baheal Medical. The latest investment will boost capital for production growth and further international deployment.
Nevertheless, ZAP competes with established radiosurgery providers, including Elekta's Gamma Knife platform. Transforming installations into recurring sales will remain a key aspect as the company scales. The patient metrics and system deliveries reported by the company demonstrate commercial progress. Further adoption will depend on clinical confidence, economic viability for providers, and the company's ability to deliver systems efficiently. This funding provides ZAP with additional resources to achieve these goals. Its long-term prospects will hinge on expanding the use of existing radiosurgery while carefully evaluating new applications in neuroscience.
